Des-serine-proline brain natriuretic peptide 3-32 in cardiorenal regulation

Guido Boerrigter, Lisa C. Costello-Boerrigter, Gail J. Harty, Harald Lapp, John C Jr. Burnett

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

Brain natriuretic peptide (BNP 1-32) plays an important physiologic role in cardiorenal homeostasis. Recently, it has been reported that BNP 1-32 is rapidly cleaved by the ubiquitous enzyme dipeptidyl peptidase IV to BNP 3-32, which lacks the two NH2-terminal amino acids of BNP 1-32. The bioactivity of BNP 3-32 in cardiorenal regulation is unknown. We hypothesized that BNP 3-32 has reduced vasodilating and natriuretic bioactivity compared with BNP 1-32 in vivo. Synthetic human BNP 3-32 and BNP 1-32 were administered to eight anesthetized normal canines. After baseline measurements, BNP 1-32 at 30 ng·kg-1·min-1 was administered, followed by a washout, a postinfusion clearance, and a clearance with an equimolar dose of BNP 3-32. In four studies, the sequence of BNP 1-32 and BNP 3-32 infusion was reversed. Peptides were compared by analyzing the changes from the respective preinfusion clearance to the respective infusion clearance. *P < 0.05 between peptides. BNP 3-32, unlike BNP 1-32, did not decrease mean arterial pressure (0 ± 1 vs. -7 ± 2* mmHg, respectively) and did not increase renal blood flow (+12 ± 10 vs. +52 ± 10* ml/min). Effects on heart rate and cardiac output were similar. Urinary sodium excretion increased 128 ± 18 μeq/min with BNP 3-32 and 338 ± 40* μeq/min with BNP 1-32. Urine flow increased 1.1 ± 0.2 ml/min with BNP 3-32 and 2.8 ± 0.4* ml/min with BNP 1-32. Plasma BNP immunoreactivity was lower with BNP 3-32, suggesting accelerated degradation. In this study, BNP 3-32 showed reduced natriuresis and diuresis and a lack of vasodilating actions compared with BNP 1-32.

Original languageEnglish (US)
JournalAmerican Journal of Physiology - Regulatory Integrative and Comparative Physiology
Volume292
Issue number2
DOIs
StatePublished - Feb 2007

Fingerprint

Brain Natriuretic Peptide
Proline
Serine
Dipeptidyl Peptidase 4

Keywords

  • BNP 3-32
  • Cardiorenal regulation
  • Enzymatic degradation product
  • Hormone

ASJC Scopus subject areas

  • Physiology

Cite this

Des-serine-proline brain natriuretic peptide 3-32 in cardiorenal regulation. / Boerrigter, Guido; Costello-Boerrigter, Lisa C.; Harty, Gail J.; Lapp, Harald; Burnett, John C Jr.

In: American Journal of Physiology - Regulatory Integrative and Comparative Physiology, Vol. 292, No. 2, 02.2007.

Research output: Contribution to journalArticle

@article{48cb9a9a746a40aa9dac29f75b639374,
title = "Des-serine-proline brain natriuretic peptide 3-32 in cardiorenal regulation",
abstract = "Brain natriuretic peptide (BNP 1-32) plays an important physiologic role in cardiorenal homeostasis. Recently, it has been reported that BNP 1-32 is rapidly cleaved by the ubiquitous enzyme dipeptidyl peptidase IV to BNP 3-32, which lacks the two NH2-terminal amino acids of BNP 1-32. The bioactivity of BNP 3-32 in cardiorenal regulation is unknown. We hypothesized that BNP 3-32 has reduced vasodilating and natriuretic bioactivity compared with BNP 1-32 in vivo. Synthetic human BNP 3-32 and BNP 1-32 were administered to eight anesthetized normal canines. After baseline measurements, BNP 1-32 at 30 ng·kg-1·min-1 was administered, followed by a washout, a postinfusion clearance, and a clearance with an equimolar dose of BNP 3-32. In four studies, the sequence of BNP 1-32 and BNP 3-32 infusion was reversed. Peptides were compared by analyzing the changes from the respective preinfusion clearance to the respective infusion clearance. *P < 0.05 between peptides. BNP 3-32, unlike BNP 1-32, did not decrease mean arterial pressure (0 ± 1 vs. -7 ± 2* mmHg, respectively) and did not increase renal blood flow (+12 ± 10 vs. +52 ± 10* ml/min). Effects on heart rate and cardiac output were similar. Urinary sodium excretion increased 128 ± 18 μeq/min with BNP 3-32 and 338 ± 40* μeq/min with BNP 1-32. Urine flow increased 1.1 ± 0.2 ml/min with BNP 3-32 and 2.8 ± 0.4* ml/min with BNP 1-32. Plasma BNP immunoreactivity was lower with BNP 3-32, suggesting accelerated degradation. In this study, BNP 3-32 showed reduced natriuresis and diuresis and a lack of vasodilating actions compared with BNP 1-32.",
keywords = "BNP 3-32, Cardiorenal regulation, Enzymatic degradation product, Hormone",
author = "Guido Boerrigter and Costello-Boerrigter, {Lisa C.} and Harty, {Gail J.} and Harald Lapp and Burnett, {John C Jr.}",
year = "2007",
month = "2",
doi = "10.1152/ajpregu.00569.2006",
language = "English (US)",
volume = "292",
journal = "American Journal of Physiology - Renal Fluid and Electrolyte Physiology",
issn = "1931-857X",
publisher = "American Physiological Society",
number = "2",

}

TY - JOUR

T1 - Des-serine-proline brain natriuretic peptide 3-32 in cardiorenal regulation

AU - Boerrigter, Guido

AU - Costello-Boerrigter, Lisa C.

AU - Harty, Gail J.

AU - Lapp, Harald

AU - Burnett, John C Jr.

PY - 2007/2

Y1 - 2007/2

N2 - Brain natriuretic peptide (BNP 1-32) plays an important physiologic role in cardiorenal homeostasis. Recently, it has been reported that BNP 1-32 is rapidly cleaved by the ubiquitous enzyme dipeptidyl peptidase IV to BNP 3-32, which lacks the two NH2-terminal amino acids of BNP 1-32. The bioactivity of BNP 3-32 in cardiorenal regulation is unknown. We hypothesized that BNP 3-32 has reduced vasodilating and natriuretic bioactivity compared with BNP 1-32 in vivo. Synthetic human BNP 3-32 and BNP 1-32 were administered to eight anesthetized normal canines. After baseline measurements, BNP 1-32 at 30 ng·kg-1·min-1 was administered, followed by a washout, a postinfusion clearance, and a clearance with an equimolar dose of BNP 3-32. In four studies, the sequence of BNP 1-32 and BNP 3-32 infusion was reversed. Peptides were compared by analyzing the changes from the respective preinfusion clearance to the respective infusion clearance. *P < 0.05 between peptides. BNP 3-32, unlike BNP 1-32, did not decrease mean arterial pressure (0 ± 1 vs. -7 ± 2* mmHg, respectively) and did not increase renal blood flow (+12 ± 10 vs. +52 ± 10* ml/min). Effects on heart rate and cardiac output were similar. Urinary sodium excretion increased 128 ± 18 μeq/min with BNP 3-32 and 338 ± 40* μeq/min with BNP 1-32. Urine flow increased 1.1 ± 0.2 ml/min with BNP 3-32 and 2.8 ± 0.4* ml/min with BNP 1-32. Plasma BNP immunoreactivity was lower with BNP 3-32, suggesting accelerated degradation. In this study, BNP 3-32 showed reduced natriuresis and diuresis and a lack of vasodilating actions compared with BNP 1-32.

AB - Brain natriuretic peptide (BNP 1-32) plays an important physiologic role in cardiorenal homeostasis. Recently, it has been reported that BNP 1-32 is rapidly cleaved by the ubiquitous enzyme dipeptidyl peptidase IV to BNP 3-32, which lacks the two NH2-terminal amino acids of BNP 1-32. The bioactivity of BNP 3-32 in cardiorenal regulation is unknown. We hypothesized that BNP 3-32 has reduced vasodilating and natriuretic bioactivity compared with BNP 1-32 in vivo. Synthetic human BNP 3-32 and BNP 1-32 were administered to eight anesthetized normal canines. After baseline measurements, BNP 1-32 at 30 ng·kg-1·min-1 was administered, followed by a washout, a postinfusion clearance, and a clearance with an equimolar dose of BNP 3-32. In four studies, the sequence of BNP 1-32 and BNP 3-32 infusion was reversed. Peptides were compared by analyzing the changes from the respective preinfusion clearance to the respective infusion clearance. *P < 0.05 between peptides. BNP 3-32, unlike BNP 1-32, did not decrease mean arterial pressure (0 ± 1 vs. -7 ± 2* mmHg, respectively) and did not increase renal blood flow (+12 ± 10 vs. +52 ± 10* ml/min). Effects on heart rate and cardiac output were similar. Urinary sodium excretion increased 128 ± 18 μeq/min with BNP 3-32 and 338 ± 40* μeq/min with BNP 1-32. Urine flow increased 1.1 ± 0.2 ml/min with BNP 3-32 and 2.8 ± 0.4* ml/min with BNP 1-32. Plasma BNP immunoreactivity was lower with BNP 3-32, suggesting accelerated degradation. In this study, BNP 3-32 showed reduced natriuresis and diuresis and a lack of vasodilating actions compared with BNP 1-32.

KW - BNP 3-32

KW - Cardiorenal regulation

KW - Enzymatic degradation product

KW - Hormone

UR - http://www.scopus.com/inward/record.url?scp=33846794760&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846794760&partnerID=8YFLogxK

U2 - 10.1152/ajpregu.00569.2006

DO - 10.1152/ajpregu.00569.2006

M3 - Article

C2 - 17068158

AN - SCOPUS:33846794760

VL - 292

JO - American Journal of Physiology - Renal Fluid and Electrolyte Physiology

JF - American Journal of Physiology - Renal Fluid and Electrolyte Physiology

SN - 1931-857X

IS - 2

ER -